Page 52 - Read Online

Page 12 of 13 Anugwom et al. Hepatoma Res 2022;8:7 https://dx.doi.org/10.20517/2394-5079.2021.123

43. Anugwom CM, Parekh JR, Hwang C, MacConmara M, Lee WM, Leventhal TM. Comparison of clinical outcomes of induction
regimens in patients undergoing liver transplantation for acute liver failure. Liver Transpl 2021;27:27-33. DOI PubMed
44. Cangemi M, Montico B, Faè DA, Steffan A, Dolcetti R. Dissecting the multiplicity of immune effects of immunosuppressive drugs to
better predict the risk of de novo malignancies in solid organ transplant patients. Front Oncol 2019;9:160. DOI PubMed PMC
45. Wai LE, Fujiki M, Takeda S, Martinez OM, Krams SM. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function.
Transplantation 2008;85:145-9. DOI PubMed PMC
46. Colic M, Stojic-Vukanic Z, Pavlovic B, Jandric D, Stefanoska I. Mycophenolate mofetil inhibits differentiation, maturation and
allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 2003;134:63-9. DOI PubMed PMC
47. Bhat M, Mara K, Dierkhising R, Watt KD. Gender, race and disease etiology predict de novo malignancy risk after liver
transplantation: insights for future individualized cancer screening guidance. Transplantation 2019;103:91-100. DOI PubMed
48. Mathur A, Franco ES, Leone JP, et al. Obesity portends increased morbidity and earlier recurrence following liver transplantation for
hepatocellular carcinoma. HPB (Oxford) 2013;15:504-10. DOI PubMed PMC
49. Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-
analysis. Liver Transpl 2012;18:62-9. DOI PubMed
50. Jiang Y, Villeneuve PJ, Fenton SS, Schaubel DE, Lilly L, Mao Y. Liver transplantation and subsequent risk of cancer: findings from a
Canadian cohort study. Liver Transpl 2008;14:1588-97. DOI PubMed
51. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol
2001;34:84-91. DOI PubMed
52. Sapisochin G, Goldaracena N, Astete S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and
analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol 2015;22:2286-94. DOI PubMed
53. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J
Clin Oncol 1999;17:324-31. DOI PubMed
54. Gomez-Martin C, Bustamante J, Castroagudin JF, et al. Efficacy and safety of sorafenib in combination with mammalian target of
rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012;18:45-52. DOI PubMed
55. Haanen JBAG, Carbonnel F, Robert C, et al; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv119-42. DOI PubMed
56. Biondani P, De Martin E, Samuel D. Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient. Ann Oncol
2018;29:286-7. DOI PubMed
57. De Toni EN, Gerbes AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient.
Gastroenterology 2017;152:1631-3. DOI
58. Anugwom C, Leventhal T. Nivolumab-induced autoimmune-like cholestatic hepatitis in a liver transplant recipient. ACG Case Rep J
2020;7:e00416. DOI PubMed PMC
59. Friend BD, Venick RS, McDiarmid SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two
patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer 2017;64:e26682. DOI PubMed
60. Owoyemi I, Vaughan LE, Costello CM, et al. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are
treated with immune checkpoint inhibitors: a single-center analysis. Cancer 2020;126:4780-7. DOI PubMed PMC
61. Wang TF, Khorana AA, Carrier M. Thrombotic complications associated with immune checkpoint inhibitors. Cancers (Basel)
2021;13:4606. DOI PubMed PMC
62. Moik F, Chan WE, Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune
checkpoint inhibitor therapy. Blood 2021;137:1669-78. DOI PubMed PMC
63. López-Cortés A, Abarca E, Silva L, et al. Identification of key proteins in the signaling crossroads between wound healing and cancer
hallmark phenotypes. Sci Rep 2021;11:17245. DOI PubMed PMC
64. Elias AW, Kasi PM, Stauffer JA, et al. The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: a
retrospective study. Front Oncol 2017;7:121. DOI PubMed PMC
65. Sun J, Kirichenko DA, Chung JL, et al. Perioperative outcomes of melanoma patients undergoing surgery after receiving
immunotherapy or targeted therapy. World J Surg 2020;44:1283-93. DOI PubMed
66. Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an
institutional experience and a systematic review of the literature. J Immunother Cancer 2019;7:106. DOI PubMed PMC
67. Gassmann D, Weiler S, Mertens JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature
research. Transplant Direct 2018;4:e376. DOI PubMed PMC
68. Kumar V, Shinagare AB, Rennke HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and
systematic review of literature. Oncologist 2020;25:505-14. DOI PubMed PMC
69. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host
disease lethality by an IFN-gamma-dependent mechanism. J Immunol 2003;171:1272-7. DOI PubMed
70. Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients. United European Gastroenterol J 2018;6:970-3.
DOI PubMed PMC
71. Chen GH, Wang GB, Huang F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic
necrosis in the immediate postoperative period. Transpl Immunol 2021;66:101386. DOI PubMed
72. Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation? Am J Transplant 2021;21:1979-80.
DOI PubMed
73. Qiao ZY, Zhang ZJ, Lv ZC, et al. Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular